Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 9/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 9/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 9/20 | 0.53 |
| ▸ | RELA | Q04206 | 9/20 | 0.53 |
| ▸ | FOS | P01100 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423492 | 0.77 | JUN (0.60) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL4425453 | 0.76 | JUN (0.59) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL8543216 | 0.76 | KDM4E (0.72) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL336184 | 0.75 | NFKB1 (0.69) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL131646 | 0.75 | NFKB1 (0.58) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL3283794 | 0.75 | JUN (0.58) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL17393706 | 0.75 | JUN (0.58) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL12844275 | 0.75 | JUN (0.58) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL30574458 | 0.75 | NFKB1 (0.58) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL2434552 | 0.74 | TUBB4A (0.56) | KDM4EALDH1A1SMN1; SMN2HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142509-B1 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8349868-B2 | Azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8048894-B2 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2155746-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2142509-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | Amgen, Inc (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008130600-A2 | QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | AMGEN INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | EGLN3, EGLN2, HIF1AN | JUN 1723/4885NFKB1 528/4885NFKB2 492/4885 |
| US-20090156605-A1 | Quinolones and azaquinolones that inhbit prolyl hydroxylase | EGLN3, HIF1AN, EGLN2 | JUN 1311/4885NFKB1 591/4885NFKB2 706/4885 |
| US-20110224248-A1 | AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE | HIF1AN, EGLN3, EGLN2 | JUN 1667/4885NFKB1 550/4885NFKB2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.